Keywords: vr776, achieves, clinical, proof, concept, pe, chippenham

VR776 achieves clinical proof of concept in PE

Article | 28 May 2007

Print This

Chippenham, UK-based Vectura says that data from a Phase IIa proof-of-concept clinical study of VR776, its candidate treatment for premature ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in